Matched preclinical designs for improved translatability

Sci Transl Med. 2017 May 10;9(389):eaal4101. doi: 10.1126/scitranslmed.aal4101.

Tero Aittokallio^{1

2

3

4}, Andreas Scherer^{1

2

3

4}, Matti Poutanen^{1

2

3

4}, Leonard P Freedman^{1

2

3

4}

¹ Tero Aittokallio is an EMBL Group Leader at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, FI 00014 Helsinki, Finland, and a Professor in the Department of Mathematics and Statistics, University of Turku, FI 20014 Turku, Finland.
² Andreas Scherer is a Project Director at FIMM, University of Helsinki, FI 00014 Helsinki, Finland, and National Coordinator in Finland for the European Infrastructure for Translational Medicine (EATRIS).
³ Matti Poutanen is a Professor in the Department of Physiology and Director of Turku Center for Disease Modeling (TCDM), Institute of Biomedicine, University of Turku, FI 20014 Turku, Finland.
⁴ Leonard P. Freedman is the Founding President of the Global Biological Standards Institute (GBSI), Washington, DC 20036, USA. Email: lfreedman@gbsi.org.

Abstract

A more stratified preclinical design strategy will increase the statistical power and reproducibility of animal studies and their translatability.